TY - JOUR
T1 - Transformation of Hydrophilic Drug into Oil-Miscible Ionic Liquids for Transdermal Drug Delivery
AU - Md Moshikur, Rahman
AU - Shimul, Islam Md
AU - Uddin, Shihab
AU - Wakabayashi, Rie
AU - Moniruzzaman, Muhammad
AU - Goto, Masahiro
N1 - Funding Information:
The authors thank Frank Kitching, M.Sc., from Edanz ( https://jp.edanz.com/ac ) for editing a draft of this manuscript. The authors acknowledge financial support from the Japan Society for the Promotion of Science (KAKENHI Numbers JP22K18314 and JP21F21051). R.M.M. thanks the JSPS for providing a fellowship (P21051) with a research grant (JP21F21051).
Publisher Copyright:
© 2022 American Chemical Society.
PY - 2022/12/21
Y1 - 2022/12/21
N2 - The transdermal delivery of hydrophilic drugs remains challenging owing to their poor ability to permeate the skin; formulation with oil media is difficult without adding chemical permeation enhancers or co-solvents. Herein, we synthesized 12 oil-miscible ionic liquid (IL) drugs comprising lidocaine-, imipramine-, and levamisole (Lev)-hydrochloride with fatty acid permeation enhancers, i.e., laurate, oleate, linoleate, and stearate as counterions. A set of in vitro and in vivo studies was performed to investigate the potency and deliverability of the transdermal drug formulations. All of the synthesized compounds were freely miscible with pharmaceutically acceptable solvents/agents (i.e., ethanol, N-methyl pyrrolidone, Tween 20, and isopropyl myristate (IPM)). In vitro permeation studies revealed that the oleate-based Lev formulation had 2.6-fold higher skin permeation capability than the Lev salts and also superior ability compared with the laurate-, linoleate-, and stearate-containing samples. Upon in vivo transdermal administration to mice, the peak plasma concentration, elimination half-life, and area under the plasma concentration curve values of Lev-IL were 4.6-, 2.9-, and 5.4-fold higher, respectively, than those of the Lev salt. Furthermore, in vitro skin irritation and in vivo histological studies have demonstrated that Lev-IL has excellent biocompatibility compared with a conventional ionic liquid-based carrier. The results indicate that oil-miscible IL-based drugs provide a simple and scalable strategy for the design of effective transdermal drug delivery systems.
AB - The transdermal delivery of hydrophilic drugs remains challenging owing to their poor ability to permeate the skin; formulation with oil media is difficult without adding chemical permeation enhancers or co-solvents. Herein, we synthesized 12 oil-miscible ionic liquid (IL) drugs comprising lidocaine-, imipramine-, and levamisole (Lev)-hydrochloride with fatty acid permeation enhancers, i.e., laurate, oleate, linoleate, and stearate as counterions. A set of in vitro and in vivo studies was performed to investigate the potency and deliverability of the transdermal drug formulations. All of the synthesized compounds were freely miscible with pharmaceutically acceptable solvents/agents (i.e., ethanol, N-methyl pyrrolidone, Tween 20, and isopropyl myristate (IPM)). In vitro permeation studies revealed that the oleate-based Lev formulation had 2.6-fold higher skin permeation capability than the Lev salts and also superior ability compared with the laurate-, linoleate-, and stearate-containing samples. Upon in vivo transdermal administration to mice, the peak plasma concentration, elimination half-life, and area under the plasma concentration curve values of Lev-IL were 4.6-, 2.9-, and 5.4-fold higher, respectively, than those of the Lev salt. Furthermore, in vitro skin irritation and in vivo histological studies have demonstrated that Lev-IL has excellent biocompatibility compared with a conventional ionic liquid-based carrier. The results indicate that oil-miscible IL-based drugs provide a simple and scalable strategy for the design of effective transdermal drug delivery systems.
UR - http://www.scopus.com/inward/record.url?scp=85144506615&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144506615&partnerID=8YFLogxK
U2 - 10.1021/acsami.2c15636
DO - 10.1021/acsami.2c15636
M3 - Article
C2 - 36508194
AN - SCOPUS:85144506615
SN - 1944-8244
VL - 14
SP - 55332
EP - 55341
JO - ACS applied materials & interfaces
JF - ACS applied materials & interfaces
IS - 50
ER -